The antigens in this vaccine are either HLA-A*01 restricted (MAGE-1, AIM-2) or HLA-A*02 restricted and derive from the following source proteins: melanoma-associated antigen-1 (MAGE-1), antigen isolated from immunoselected melanoma-2 (AIM-2), human epidermal growth factor receptor-2 (HER2/neu), tyrosinase-related protein-2 (TRP-2), glycoprotein 100 (gp100), and interleukin-13 receptor alpha 2 (IL-13Rα2). Here, DCT is linked to melanoma.